Price of EpiPens reduced by eight percent

By Admin
Meda Pharmaceuticals is reducing the price of its EpiPen Auto-Injector by over eight percent and is also launching training devices to help patients to...

Meda Pharmaceuticals is reducing the price of its EpiPen Auto-Injector by over eight percent and is also launching training devices to help patients to use EpiPens properly.

The EpiPen Auto-Injector is the market leader for the emergency treatment of severe allergic reactions (anaphylaxis) in both children and adults.

It is thought that approximately 210,000 people in the UK are at risk of anaphylaxis and rely on the life-saving treatment, which is now priced at £26.45.

To read the latest edition of Exec Digital, click here
Ryan Reynolds joins milk campaign

Happiness gene is revealed

Asthma pills as effective as inhalers

In addition to making the product more affordable, Meda is also offering free training devices, so patients will be able to practice using an EpiPen Auto Injector without its needle to help improve their self-administration techniques.

The EpiPens have been designed for use in stressful conditions and can be used by patients and caregivers often without the assistance of a healthcare professional.

Patients will also be able to register for expiry alerts from the EpiPen website to make sure their devices are within their expiry date.

Meda Pharmaceuticals have the exclusive marketing and distribution rights for the EpiPen Auto Injector, after signing a long-term agreement with Mylan Inc’s Dey Pharma.

David Bennett, General Manager, Meda UK said: “We are working very closely with the manufacturer to deliver a robust and consistent supply of EpiPen Auto-Injector which will continue to be available through Alliance Healthcare.”

He added: “Meda has long-standing expertise in allergy medicine throughout the world and we are keen to provide support to the prescriber, caregiver and patient alike.”

Anaphylaxis can be trigged by a number of allergies and its symptoms develop rapidly. Typical symptoms include swelling, breathing problems, an increased heart rate and a loss of consciousness.

The adrenaline chemical that is contained in the EpiPens works to combat these symptoms by reducing swelling and increasing blood pressure.


Featured Articles

TrueBinding’s antibody drugs fight Alzheimer’s Disease

Dongxu Sun, CEO at TrueBinding, shares how its research & antibody drug development is fighting illnesses such as Alzheimer’s Disease, stroke & more

Cardinal Health’s clinically integrated pharma supply chain

Peter Siavelis, SVP & General Manager, Health System and Provider Distribution & Services at Cardinal Health, discusses the integrated pharma supply chain

Healthcare Digital news roundup: digital healthcare & AI

This week in Healthcare Digital, we looked at digital skills for healthcare leaders, medical technology & acoustic AI used in digital cough monitoring

Hospitals must embrace IoMT device security


Mental health support for working women and mothers

Digital Healthcare

Digital evolution delivers better healthcare outcomes

Digital Healthcare